Program
IBI3002
A development code.
Its studies are mostly in Asthma · Dermatitis, Atopic, led by Innovent Biologics.
Furthest: phase 2, since Jan 15, 20263 company-led studies, 1 open or runningNext primary completion: Mar 23, 2027 (phase 2)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Innovent Biologics | 31 open or running | phase 2since Jan 15, 2026 | Jan 10, 2024 | Mar 23, 2027phase 2 · NCT07399067 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jan 10, 2024First study: phase 1 study in AsthmaFirst studyNCT06213844 · 52 enrolled · Australia
- Apr 10, 2025Phase 1 study in AsthmaNCT06947408 · 44 enrolled · China
- Jan 15, 2026Phase 2 study in Dermatitis, AtopicPhase 2 reachedNCT07399067 · 120 planned · China
Ahead
- Mar 23, 2027Primary completion: phase 2 study in Dermatitis, AtopicNCT07399067
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 3 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07399067Dermatitis, Atopic · China | 2 | Recruiting | Mar 23, 2027 | 120 |
| NCT06947408Asthma · China | 1 | Completed | May 11, 2026 | 44 |
| NCT06213844Asthma · Australia | 1 | Completed | Jul 22, 2025 | 52 |
How it is read
Names in the registry
- “IBI3002”, 3 entries
Codes read as this program: IBI3002.
Conditions, from the studies’ own filings
- Asthma, 2 studies
- Dermatitis, Atopic, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.